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ABSTRACT
Non-invasive prenatal testing (NIPT) of fetal aneuploidy using cell-free
fetal DNA is becoming part of routine clinical practice. RAPIDR
(Reliable Accurate Prenatal non-Invasive Diagnosis R package) is an
easy-to-use open-source R package that implements several pub-
lished NIPT analysis methods. The input to RAPIDR is a set of se-
quence alignment files in the BAM format, and the outputs are calls for
aneuploidy, including trisomies 13, 18, 21 and monosomy X as well as
fetal sex. RAPIDR has been extensively tested with a large sample set
as part of the RAPID project in the UK. The package contains quality
control steps to make it robust for use in the clinical setting.
Availability and implementation: RAPIDR is implemented in R and
can be freely downloaded via CRAN from here: http://cran.r-project.
org/web/packages/RAPIDR/index.html.
Contact: kitty.lo@ucl.ac.uk
Supplementary information: Supplementary data are available at
Bioinformatics online.
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1 INTRODUCTION
Since the first demonstration of the use of cell-free DNA
(cfDNA) to detect aneuploidy (Chiu et al., 2008; Fan et al.,
2008), many groups around the world have reported large studies
showing high sensitivities and specificities for the detection of
trisomies 13, 18 and 21 (Jiang et al., 2012; Palomaki et al.,
2011; Sehnert et al., 2011). In contrast to invasive methods
such as amniocentesis, non-invasive prenatal testing (NIPT)
uses cfDNA in maternal plasma and does not present a risk of
miscarriage. Currently, outside the context of research studies,
NIPT for aneuploidy is only available from commercial
providers.
To perform NIPT, cfDNA is extracted from maternal plasma
and sequenced using short reads and high-throughput DNA
sequencing. Sequenced reads are aligned to the reference
human genome using a short read aligner. Aneuploidy is called
if the number of reads mapped to each chromosome differs from
its expectation based on a comparison with a set of baseline
samples. The general approach is usually referred to as a read
depth strategy.
A number of factors influence test performance, for example
the fetal fraction (i.e. the proportion of reads originating from
the fetus), and other technical parameters such as read length
and coverage (Fan and Quake, 2010). The choice of sequencing
parameters needs to be balanced against costs. Previous studies
have shown that an acceptable level of test sensitivity can be
reached with relatively short read lengths (36–52bp) and
modest coverage (2–10 million reads per sample) (Liang et al.,
2013; Sehnert et al., 2011).
Here, we present a flexible and robust R package for NIPT
analysis called RAPIDR (Reliable Accurate Prenatal non-
Invasive Diagnosis R package). RAPIDR combines several ana-
lytical techniques that have been proposed for NIPT analysis and
has been tested with a large sample set from the RAPID project
(NIHR funded project to evaluate the use of NIPT). RAPID
validation results can be found in the Supplementary Material
(Supplementary Figs S1–S4, Supplementary Text S1 and
Supplementary Tables S1 and S2).
2 CORRECTION FOR TECHNICAL ARTEFACTS
The NIPT workflow is illustrated in Figure 1a. RAPIDR handles
the processing steps after reads have been sequenced and aligned,
i.e. it starts from the BAM files. It uses the Rsamtools and the
GenomicRanges R packages to parse the BAM files and count
the number of reads in predefined bins (20 kb as default bin
length, which must be sufficiently large to obtain at least 20
reads per bin).
Raw read counts from high-throughput sequencing technolo-
gies typically do not follow theoretical counting statistics. The
excess variance, introduced in part by the polymerase chain re-
action steps, is correlated with the GC content of the DNA se-
quence. Various methods have been proposed to correct for these
biases. RAPIDR implements two methods from the literature:
the normalized chromosome value (NCV) method (Sehnert et al.,
2011) and weighting of counts by GC content bin (Fan and
Quake, 2010). These methods require a reference sample set, in
contrast to the open source tool described by Straver et al.
(2014). NCV computes the ratio between the counts mapped to
the chromosome of interest and another chromosome. The
chromosome used in the denominator is chosen to minimize
the variance of the NCV ratios. In the GC bin weighting
method (Fan and Quake, 2010), we first determine the read
count in each bin, and then compute the average count as a
function of GC content (using discrete intervals of 0.5% for
GC proportion). Counts in each bin are then weighted by
Wi=M=Mi, where M is the average counts across all bins and
Mi is the average count in bin i. We also implemented a third*To whom correspondence should be addressed.
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method for GC correction based on principal component ana-
lysis (PCA), which as far we know, has not been used in the
context of NIPT. In the PCA method, we first use the euploid
samples in the baseline set to find the principal components by
treating the count ratios in each bin as a variable. Then, we
regress the count ratios in each bin with the first 10 principal
components, with the assumption that they represent systematic
noise. We find that PCA provides higher sensitivity than GC bin
weighting correction in exchange for lower specificity
(Supplementary Table S1).
Low complexity and repetitive regions are common in the
human genome, which complicates the alignment of short
sequencing reads. We recommend only keeping uniquely
mapped reads. RAPIDR provides the option to mask out
parts of genome known to be of low complexity. By default, it
excludes bins with abnormally high read counts from the
analysis.
3 CALLING OF ANEUPLOIDY AND FETAL SEX
Once artifacts have been removed from the read counts, the next
step is for RAPIDR to create a baseline using a set of reference
samples with known outcomes and fetal sex. For each sample,
RAPIDR calculates the ratio of reads mapped to each chromo-
some compared with the reads mapped to all the autosomes (call
this ratio rij for chromosome i and sample j). Using the set of
reference samples without known aneuploidy, it then computes
the mean (i) and SD (i) of rij for chromosomes 21, 18 and 13.
To call chromosomal abnormalities, it calculates a z-score zij for
each sample–chromosome pair (Fig. 1b). A trisomy is called if
that z-score exceeds a specified threshold (typically z43). We
estimate that a relatively small reference sample set is sufficient
to provide accurate results, however a bigger reference sample set
would ensure any inter-run variabilities are captured.
(Supplementary Text S2).
An important issue is technical sample-to-sample variability. If
a sample is technically too distinct, it will not be appropriate to
include it in the baseline. We propose quality control checks to
ensure that such technical issues are not affecting the calls. One
useful check is to make sure that the z-score for all autosomes
(aside from the chromosomes for which we suspect aneuploidy)
fall between the expected range. RAPIDR provides functions to
report and visualize this easily, and Figure 1b shows the quality
control output from one sample.
A different and slightly more complex process is required to
determine fetal sex and to call monosomy X abnormalities.
Given an unknown sample, the z-score is calculated for chr X
and chr Y (zX and zY), with the following rules being applied
sequentially—if zY43, the sample is called male; if zX4 2, the
sample is called female; if zX5 3, the sample is called as mono-
somy X; finally, if zX is between –2 and –3, then the sample sex is
called as unknown (Fig. 1c). To improve the accuracy of fetal sex
calling, we also excluded bins in chr Y with a high number of
counts mapped from females, e.g. the pseudo-autosomal region
of chr Y.
For euploid males, RAPIDR also estimates the fetal fraction
using the method from Rava et al. (2014). Fetal fraction is an
important determinant of NIPT sensitivity, but it cannot be
measured directly using the protocol we described.
4 CONCLUSION
In this article, we described the RAPIDR package for NIPT of
fetal aneuploidies. RAPIDR has been validated using4700 sam-
ples and delivers an acceptable level of specificity and sensitivity
for T21, T18, T13 and monosomy X. The system requirement for
RAPIDR is modest (Supplementary Text S3). Future work on
RAPIDR will include evaluating strategies to detect sub-chromo-
somal abnormalities.
(a)
(b)
(c)
Fig. 1. (a) Workflow of NIPT; (b) The z-scores across all the autosomes
for a T21 sample, the triangles highlight chromosomes 13, 18 and 21 for
which we test for aneuploidy; (c) Visual display of the criteria used to call
fetal sex and chromosome aneuploidy
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